ACAD stock news

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR )( announced a deal to be bought by Danish pharma company Lundbeck) AxsomeTherapeutics Inc (NASDAQ: AXSM ) Kodiak Sciences Inc (NASDAQ: KOD )(announced positive emerging durability data from a Phase 1b study of its pipeline asset KSI-301 in wet age-related macular degeneration) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) -mAbs Therapeutics, Inc (NASDAQ: YMAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 16) BioNano Genomics Inc (NASDAQ: BNGO ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Myovant Sciences Ltd (NYSE: MYOV ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Acceleron To Discontinue Development Of Mid-Stage Asset To Treat Muscular Dystrophy Acceleron Pharma Inc (NASDAQ: XLRN ) said it's halting the development of ACE-083 as a treatment option for patients with facioscapulohumeral muscular dystrophy. Read more
Jim Cramer takes a look at Ford, Domo, Acadia Pharmaceuticals, Forescout Technologies, Covetrus, Arrow Electronics and more….DOMO Read more

Positive Developments for These 3 Biotech Stocks

01:45pm, Wednesday, 11'th Sep 2019
We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics….ACAD Read more
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares, which rallied over 63% Monday following positive results from its pimavanserin in dementia-related psychosis, were seeing further upward momentum Tuesday. The Analysts H.C. Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Acadia with a $60 price target. Canaccord Genuity analyst Sumant Kulkarni upgraded the stock from Hold to Buy and raised the price target from $29 to $50. HC Wainwright Remains Bullish On Fundamentals Acadia delivered another pleasant surprise for investors by way of a positive interim analysis from the Phase 3 HARMONY study, which showed pimavanserin's statistically superior efficacy compared to placebo in time to relapse of dementia-related psychosis, Fein said in a Tuesday note. Acadia's "pipeline in a drug" thesis is now validated with a much bigger population, the analyst said. The analyst sees the dementia-related psychosis opportunity alone as sufficient to fuel pimavanserin growth in … Full story available on Benzinga. Read more
ACADIA Pharmaceuticals' (ACAD) Parkinson's psychosis drug, Nuplazid, meets primary endpoint earlier than expected in late-stage label expansion study evaluating it in patients with dementia-related psychosis. Read more

Will ACADIA Continue to Surge Higher?

02:59pm, Tuesday, 10'th Sep 2019
As of late, it has definitely been a great time to be an investor ACADIA Pharmaceuticals. Read more
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency. Read more
Acadia's flagship drug notched a key late-stage win today. Read more

ACADIA Enters Oversold Territory

01:05pm, Monday, 09'th Sep 2019
ACADIA Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. Read more
Shares of Acadia Pharmaceuticals Inc. rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial… Read more
As of late, it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc. (ACAD). Read more
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Acadia Pharmaceuticals Inc. shares dropped in the extended session Monday after the biotech drug maker said its schizophrenia treatment did not pass a… Read more
The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month. Read more

Proudly made at